A recent study indicates that patients who discontinue blockbuster weight-loss injections like semaglutide or tirzepatide can put back on shed pounds at a significantly accelerated pace than those who halt traditional diet and exercise plans.
Published data in a prominent medical journal demonstrates that while overweight individuals often shed a large proportion of their total mass while undergoing treatment, the mass returns at an average rate of 0.8 kg per month after stopping.
"People purchasing these drugs need to be aware of the potential of quick weight regain when the treatment ends," warns researcher Dr. Susan Jebb.
This pace of regain suggests a return to original weight within about 18 months.
Weighing Treatments
The analysis, which examined dozens of studies involving over 9,000 of patients, contrasted the results of these new drugs with other pills.
The team point out that individuals who shed pounds through lifestyle changes alone usually have a slower weight regain—perhaps 100 grams monthly—once they finish.
Explaining the Quick Rebound
Nutrition scientists believe the mechanism of the injections accounts for the heightened rebound.
The injections mimic a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.
"Sustained high doses of GLP-1 levels far above than normal might result in the system to produce less of its own natural GLP-1, and could diminish responsiveness to its effects," said Dr. Adam Collins, a nutrition specialist.
"Stopping of this hormone supplement results in appetite is unsuppressed, making excessive eating much more probable."
A Chronic Disease?
The NHS recommend the injections for people with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
A number of clinicians argue that, considering the likelihood of relapse, the treatment might need to be ongoing.
This opinion is supported by pharmaceutical companies, who note that the findings "emphasize the long-term character of excess weight," similar to managing conditions like high blood pressure.
User Accounts
Users who have stopped the jabs explain a powerful return of hunger.
"I experienced a trigger that goes on and you become starving," recalled a patient.
The struggle is worsened if users have not established sustainable lifestyle or habit changes during therapy.
Significant Use
Figures indicate that a significant number of adults in the UK have used weight-loss jabs in the past year, with desire being substantial.
- Adoption is more common among women compared to men.
- The 40s and 50s age group shows the greatest usage rates.
- Many obtain the drugs through private prescriptions rather than public health services.
In conclusion, clinicians emphasize that while GLP-1 drugs are powerful agents for weight loss, they are not a standalone fix and lasting health benefits hinges on integrated behavioural changes.